fundamentals!, page-6

What I find mildly amusing is that only about 6-8 weeks ago, Dendreon was being criticised and the share price had a decent sized correction, because it was deemed they didn't have sufficient production capacity to meet demand.

Wow, did that turn out to be a blind alley.

Now they're in scramble mode to fix the marketing/cash flow issue. There's no controversy regarding the selling price per se, and cuts to the Medicare budget don't affect drug and vaccine makers. They just need to solve the doctors outlay/reimbursement issue. DNDN has already begun this with a rollout of the on-line (2 week) claim system. Just a shame they didn't get their act together earlier.

Rightly or wrongly and like it or not, once listed on the Nasdaq, US investors are going to equate PRR with DNDN. They will want reassurance that PRR are not as accident prone and have gone to school on DNDN's mistakes.

Once they have that level of confidence and Provenge sales show signs of improvement (hopefully in the next quarter) I believe they'll start jumping on the PRR band wagon with gusto. Any good progress news on Cvac will push that along nicely.

As to what tomorrow will bring in the wake of the US credit downgrade... I'm just holding my breath like eveyone else.

Que sera, sera!